Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.

Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, Hwang CI, Öhlund D, Chio IIC, Baker LA, Filippini D, Wright K, Bapiro TE, Huang P, Smith P, Yu KH, Jodrell DI, Park Y, Tuveson DA.

Clin Cancer Res. 2019 Sep 6. doi: 10.1158/1078-0432.CCR-19-1398. [Epub ahead of print]

PMID:
31492749
2.

Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells.

Tian C, Clauser KR, Öhlund D, Rickelt S, Huang Y, Gupta M, Mani DR, Carr SA, Tuveson DA, Hynes RO.

Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19609-19618. doi: 10.1073/pnas.1908626116. Epub 2019 Sep 4.

PMID:
31484774
3.

Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer.

Franklin O, Billing O, Öhlund D, Berglund A, Herdenberg C, Wang W, Hellman U, Sund M.

J Pathol Clin Res. 2019 Apr;5(2):130-141. doi: 10.1002/cjp2.122. Epub 2018 Dec 13.

4.

CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.

Honda K, Katzke VA, Hüsing A, Okaya S, Shoji H, Onidani K, Olsen A, Tjønneland A, Overvad K, Weiderpass E, Vineis P, Muller D, Tsilidis K, Palli D, Pala V, Tumino R, Naccarati A, Panico S, Aleksandrova K, Boeing H, Bueno-de-Mesquita HB, Peeters PH, Trichopoulou A, Lagiou P, Khaw KT, Wareham N, Travis RC, Merino S, Duell EJ, Rodríguez-Barranco M, Chirlaque MD, Barricarte A, Rebours V, Boutron-Ruault MC, Romana Mancini F, Brennan P, Scelo G, Manjer J, Sund M, Öhlund D, Canzian F, Kaaks R.

Int J Cancer. 2019 Apr 15;144(8):1877-1887. doi: 10.1002/ijc.31900. Epub 2018 Dec 4.

5.

Stromal biology and therapy in pancreatic cancer: ready for clinical translation?

Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM.

Gut. 2019 Jan;68(1):159-171. doi: 10.1136/gutjnl-2018-316451. Epub 2018 Sep 3. Review.

PMID:
30177543
6.

VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival.

Morin E, Sjöberg E, Tjomsland V, Testini C, Lindskog C, Franklin O, Sund M, Öhlund D, Kiflemariam S, Sjöblom T, Claesson-Welsh L.

J Pathol. 2018 Nov;246(3):311-322. doi: 10.1002/path.5141. Epub 2018 Sep 4.

7.

Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer.

Franklin O, Jonsson P, Billing O, Lundberg E, Öhlund D, Nyström H, Lundin C, Antti H, Sund M.

Ann Surg. 2018 Apr;267(4):775-781. doi: 10.1097/SLA.0000000000002124.

8.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA.

J Exp Med. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23.

9.

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer.

Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Öhlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H, Hammell M, Crawford HC, Schmidt EE, Thompson CB, Pappin DJ, Sonenberg N, Tuveson DA.

Cell. 2016 Aug 11;166(4):963-976. doi: 10.1016/j.cell.2016.06.056. Epub 2016 Jul 28.

10.

Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma.

Biffi G, Öhlund D, Tuveson D.

Cell Death Differ. 2016 Aug;23(8):1265-6. doi: 10.1038/cdd.2016.50. Epub 2016 Jun 10. No abstract available.

11.

Organoid models of human and mouse ductal pancreatic cancer.

Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA.

Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.

12.

Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma.

Franklin O, Öhlund D, Lundin C, Öman M, Naredi P, Wang W, Sund M.

Cancer Biomark. 2015;15(1):1-10. doi: 10.3233/CBM-140430.

PMID:
25524936
13.

Fibroblast heterogeneity in the cancer wound.

Öhlund D, Elyada E, Tuveson D.

J Exp Med. 2014 Jul 28;211(8):1503-23. doi: 10.1084/jem.20140692. Review.

14.

Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop.

Öhlund D, Franklin O, Lundberg E, Lundin C, Sund M.

BMC Cancer. 2013 Mar 26;13:154. doi: 10.1186/1471-2407-13-154.

15.

Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer.

Ohlund D, Lundin C, Ardnor B, Oman M, Naredi P, Sund M.

Br J Cancer. 2009 Jul 7;101(1):91-7. doi: 10.1038/sj.bjc.6605107. Epub 2009 Jun 2.

16.

Expression pattern and circulating levels of endostatin in patients with pancreas cancer.

Ohlund D, Ardnor B, Oman M, Naredi P, Sund M.

Int J Cancer. 2008 Jun 15;122(12):2805-10. doi: 10.1002/ijc.23468.

Supplemental Content

Loading ...
Support Center